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Background: Chlamydia pneumoniae is an obligate intracellular respiratory pathogen for humans. Infection by C.
pneumoniae may be linked etiologically to extra-respiratory diseases of aging, especially atherosclerosis. We have
previously shown that age promotes C. pneumoniae respiratory infection and extra-respiratory spread in BALB/c
mice.
Findings: Aged C57BL/6 mice had a greater propensity to develop chronic and/or progressive respiratory infections
following experimental intranasal infection by Chlamydia pneumoniae when compared to young counterparts. A
heptavalent CTL epitope minigene (CpnCTL7) vaccine conferred equal protection in the lungs of both aged and
young mice. This vaccine was partially effective in protecting against C. pneumoniae spread to the cardiovascular
system of young mice, but failed to provide cardiovascular protection in aged animals.
Conclusions: Our findings suggest that vaccine strategies that target the generation of a C. pneumoniae-specific
CTL response can protect the respiratory system of both young and aged animals, but may not be adequate to
prevent dissemination of C. pneumoniae to the cardiovascular system or control replication in those tissues in aged
animals.
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Chlamydia pneumoniae is an important respiratory
pathogen in humans [1]. Extra-respiratory spread may
be common and with consequence: C. pneumoniae or
chlamydial DNA has been detected in the coronary ar-
teries of 46% of individuals with atherosclerosis, but
rarely in individuals without coronary artery disease [2].
C. pneumoniae-specific T cells have also been detected
within atheromatous plaques [3].
Infection by C. pneumoniae is common in western
countries, at least 70% of the total population has been
infected by age 65 [4,5]. Pneumonia poses a high risk of
morbidity and mortality in aged humans, and vaccines
against respiratory pathogens are often less effective in* Correspondence: kerinf@pcom.edu
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reproduction in any medium, provided the orthe elderly [reviewed in [6]]. Thus, there is a need for
vaccine strategies that prevent both respiratory infection
and extra-respiratory spread of C. pneumoniae in aged,
as well as young individuals.
We have previously established in BALB/c mice tthat
aging was associated with impaired resolution of
respiratory C. pneumoniae infection, more extensive
inflammation and consolidation within the infected lung,
enhanced spread of C. pneumoniae to the cardiovascular
system and increased inflammation within the heart [7].
We sought to extend these findings to a genetically
disparate strain, C57BL/6, which has been shown to
mount a strong Th1-polarized immune response specific
for C. pneumoniae [8,9]. We also hypothesized that a
heptavalent cytotoxic T cell (CTL) epitope DNA mini-
gene vaccine (CpnCTL7) [10], which has been shown to
generate epitope-specific CD8+ CTL capable of IFN-γ
and TNF-α secretion and cytolytic activity against C.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mean respiratory bacterial titers in young, C. pneumo-
niae-infected C57BL/6 mice [10], would be less effective
in prevention of respiratory and cardiovascular C. pneu-
moniae infection in aged C57BL/6 mice.
Methods employed
To test this hypothesis, female C57BL/6 mice (National
Institutes of Aging) received three injections of 100 μg of
CpnCTL7 or VR1012 plasmid DNA as previously
described [10]. Twelve days after the third dose, C57BL/6
mice, at 6 and 20 months of age, were infected by intrana-
sal inoculation with 5.0 x 105 IFU of C. pneumoniae (AR-
39; ATCC, Rockville MD), in HBSS [7]. Uninfected mice
received HBSS alone. Mice were euthanized 14 or 28 days
after infection by CO2 asphyxiation. Lungs and hearts/
ascending aortae were removed, snap frozen in liquid ni-
trogen and stored at −80°C until assay.
To test for the presence of Chlamydia in tissue samples,
four-well chamber slides (Lab Tech, Naperville, Ill) were
seeded with 1.4 x 105 HEp-2 cells/well and incubated over-
night at 37°C in 5% CO2. Serial 10-fold dilutions of tissue
homogenate prepared as described previously [6] were
added to the wells. Negative control wells contained HEp-2
cells in media alone. The slides were centrifuged at 390xg
for 30 min (Sorvall Legend RT, Kendro Laboratory Pro-
ducts, Asheville, NC). After 2 h at 37°C, cycloheximide
(Sigma Scientific, St. Louis, MO, final concentration=2 μg/
ml) was added and the chamber slides were incubated for
an additional 72 h at 37°C. Slides were washed with PBS,
fixed with Cytofix/Cytoperm (BD Biosciences, San Diego,
CA) for 30 min, and washed again in PBS. Slides were trea-
ted with a 1X Perm/Wash solution (BD Biosciences, San
Diego, CA) for 15 min and stained with 0.2 μg FITC-
conjugated Chlamydia trachomatis LPS-specific antibody
(Catalog #61-C75, Fitzgerald Industries Intl., Concord, MA)
in PBS for 60 min at 37°C. Slides were washed, counter-
stained with a 1:1,000 dilution of bisBenzamide (1 μg/mL,
Sigma Scientific, St. Louis, MO) in PBS, and rinsed again.
Slides were mounted in Gel/Mount (Biomeda Corp., Foster
City, CA), cover-slipped and stored in the dark. Infected
cells were counted at 600x magnification using a Nikon
Eclipse E800 microscope. Titers were calculated as
described previously [7].
One-way analysis of variance (ANOVA) tests were per-
formed using SPSS.
The CpnCTL7 vaccine provides protection against
respiratory C. pneumoniae infection in both
young and aged C57BL/6 mice
At 14 days post-infection (p.i., Figure 1A), all (4/4) non-
vaccinated young C57BL/6 mice had evidence of C.
pneumoniae respiratory infection (mean titer = 6.0 x 104
IFU/ml, range: 1.0 x 104-5.0 x 105 IFU/ml). In contrast,the CpnCTL7 vaccine protected against respiratory C.
pneumoniae infection in all 5 infected young mice
(p = 0.001). Similarly, 3 of 4 (75%) non-vaccinated aged
mice had detectable C. pneumoniae in the lung; but
none of the 4 aged, vaccinated mice had detectable C.
pneumoniae titers at 14 days p.i. (p = 0.012). These
results suggest that the cytolytic T cell response induced
by the CpnCTL7 vaccine was of sufficient magnitude in
aged mice to provide at least temporary protection
against C. pneumoniae infection.
None of the uninfected (1 young, non-vaccinated, 2
young, vaccinated, and 3 aged, vaccinated) control mice
had detectable C. pneumoniae titers (data not shown).
At 28 days p.i., 12 out of 13 (92%) young, non-
vaccinated mice had C. pneumoniae lung titers (range:
1.0 x 102- 5.0 x 103 IFU/ml). The geometric mean titer
for non-vaccinated young mice (5.4 x 102 IFU/ml) was
approximately 100-fold lower at 28 days p.i. than at
14 days p.i. (6.0 x 104 IFU/ml), indicating that young
C57BL/6 mice control respiratory C. pneumoniae infec-
tion to some degree without vaccination. Yet, clearance of
the organism may be promoted by vaccination. At 28 days
p.i., 9 of the 15 (60%) young, vaccinated mice had no evi-
dence of C. pneumoniae in the lung (Figure 1B), compared
to only 8% (1 of 13) in the non-vaccinated group. The
remaining 6 (40%) young, vaccinated mice showed nom-
inal infection (range= 5.0 x 102-5.0 x 103 IFU/ml,
Figure 1B).
In contrast to that observed in young non-vaccinated
mice, the infection established in aged mice following
intranasal inoculation of C. pneumoniae appears to be
progressive. The geometric mean titer from lungs of aged,
unvaccinated mice at 28 days p.i. (1.9 x 104 IFU/ml) was
10-fold higher than that obtained at 14 days p.i. (1.7 x 103
IFU/ml). C. pneumoniae was detected in all (11/11) aged,
non-vaccinated C57BL/6 mice at 28 days p.i. (Figure 1B).
Still, the vaccine remains at least partially protective in
aged mice; 5 of the 11 (45%) aged, vaccinated mice were
clear of respiratory C. pneumoniae infection at 28 days p.i.
The remaining 55% of aged, vaccinated mice had lung
titers that ranged from 1.0 x 103 to 2.0 x 104 IFU/ml
(Figure 1B). The geometric mean for all aged, vaccinated
mice was 5.4 x 102 IFU/ml which is 35-fold lower than
that of aged, non-vaccinated animals, but not statistically
significant (p= 0.109). These results suggest that the CTL
response elicited in both young and aged mice still
protects against respiratory infection in at least a subset of
each group. Our results, however, indicate that a reservoir
of infection existed over the 28 day period in some vacci-
nated mice, regardless of age. It is possible that the
cytolytic response or the cytokines (including IFN-γ)
produced by the CTL, drove the course of infection into a
persistent state in some animals, as has been described by
others [11].
Figure 1 Recovery of C. pneumoniae from the lung 14 and 28 days after intranasal inoculation of 5x105 IFU 6-month-old (young) or
20-month-old (aged) C57BL/6 mice were immunized with 100 μg of CpnCTL7 (vaccine) or VR1012 plasmid DNA (vector) and
challenged intranasally with 5x105 IFU C. pneumoniae 12 days after completion of the immunization protocol. Mice were euthanized
14 days (A) or 28 days (B) after infection, the lungs were removed, and lysates prepared as described in Materials and Methods. Viable organisms
were recovered and quantified by immunofluorescent staining using FITC-conjugated Chlamydia-specific antibody (Fitzgerald 61-C75). The groups
of experimentally infected and uninfected age-matched control mice are listed on the X-axis and the number of inclusion forming units/ml of
10 % weight/volume homogenate (log10) is displayed on the Y-axis. Each dot represents the concentration (IFU/ml) of C. pneumoniae recovered
from the organ homogenate of an individual mouse. The red bars indicate the geometric mean of all animals in each group (log10) and the red
arrow indicates the limit of C. pneumoniae in the detection system. The “**” symbols indicate a statistically significant difference (p = 0.025)
between the geometric mean of respiratory titers of aged, vaccinated mice and aged mice receiving vector alone.
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uninfected mice (3 young non-vaccinated, 3 young
vaccinated, 2 aged non-vaccinated and 5 aged vaccinated
mice, data not shown).
Effect of age and vaccination status on spread of
C. pneumoniae to the cardiovascular system
Cardiovascular infection is a common sequella of respira-
tory C. pneumoniae infection in both C57BL/6 (Figure 2)
and BALB/c mice [6]. While cardiovascular infection may
be established without overt symptoms, infection may trig-
ger a chronic immune and/or inflammatory response that
would contribute to the development and/or progression of
pathology [6]. Thus, protective vaccination that would limit
or prevent the spread of C. pneumoniae to the cardiovascu-
lar system might be an effective strategy in preventing or
delaying age-related cardiovascular pathologies.
Our results show that, by 14 days p.i., all (4/4) of the
young, non-vaccinated mice showed signs of C. pneumo-
niae spread to the heart/ascending aorta (geometric
mean = 1.0 x 104 IFU/ml, range: 5.0 x 102- 5.0 x 107
IFU/ml, Figure 2A). In contrast, none (0/4) of young
vaccinated mice showed any signs of cardiovascular in-
fection at 14 days p.i. (Figure 2A). Similarly, all 4 aged,non-vaccinated animals displayed signs of cardiovascular
infection at 14 days p.i. (geometric mean= 3.9 x 104
IFU/ml, range: 1.0 x 103-1.0 x 107 IFU/ml, Figure 2A).
Only 1 of the 4 (25%) of the aged, vaccinated mice
showed demonstrable cardiovascular infection (2.5 x 103
IFU/ml) at 14 days p.i. (Figure 2A). The geometric mean
for the aged, non-vaccinated mice was 288-times higher
than that in aged, vaccinated mice (p = 0.025).
At 28 days p.i., 11 of the 13 (85%) young non-
vaccinated mice had evidence of C. pneumoniae infec-
tion in the heart/ascending aorta (range: 5.0 x 102-5.0 x
106 IFU/ml, Figure 2B). Extra-respiratory spread was
drastically reduced by vaccination in young mice. Only
40% (6 out of 15) of young vaccinated mice showed
detectable infection in the heart/ascending aorta (range:
1.0 x 103-1.0 x 105 IFU/ml, Figure 2B). The geometric
mean C. pneumoniae titer for the young, non-vaccinated
animals (5.9x103 IFU/ml) was 17-fold higher than that
of young, vaccinated animals (3.4 x 102 IFU/ml), a differ-
ence that was not statistically significant.
All (11 out of 11) of the aged, non-vaccinated animals
displayed signs of infection in the heart/ascending aorta
(range: 5.0 x 102-1.0 x 107 IFU/ml, geometric mean = 1.0
x 105 IFU/ml, Figure 2B) at 28 days p.i. The vaccine,
Figure 2 Recovery of C. pneumoniae from the heart 14 and 28 days after intranasal inoculation of 5x105 IFU 6-month-old (young) or
20-month-old (aged) C57BL/6 mice were immunized with 100 μg of CpnCTL7 (vaccine) or VR1012 plasmid DNA (vector) and
challenged intranasally with 5x105 IFU C. pneumoniae 12 days after completion of the immunization protocol. Mice were euthanized
14 days (A) or 28 days (B) after infection, the hears/ascending aortae were removed, and lysates prepared as described in Materials and Methods.
Viable organisms were recovered and quantified by immunofluorescent staining using FITC-conjugated Chlamydia-specific antibody (Fitzgerald
61-C75). The groups of experimentally infected and uninfected age-matched control mice are listed on the X-axis and the number of inclusion
forming units/ml of 10 % weight/volume homogenate (log10) is displayed on the Y-axis. Each dot represents the concentration (IFU/ml) of C.
pneumoniae recovered from the organ homogenate of an individual mouse. The red bars indicate the geometric mean of all animals in each
group (log10) and the red arrow indicates the limit of C. pneumoniae in the detection system. The “*” symbol indicates a statistically significant
difference (p = 0.001) between the geometric mean of respiratory titers of young, vaccinated mice and young mice receiving vector alone. The
“**” symbols indicate a statistically significant difference (p = 0.012) between the geometric mean of respiratory titers of aged, vaccinated mice
and aged mice receiving vector alone.
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in aged animals; 9 of 11 (82%) of aged, vaccinated mice
had detectable infections (range: 1.0 x 103 to 1.5 x 107
IFU/ml, Figure 2B) with a geometric mean of 4.5 x 104
IFU/ml. These results indicate that while vaccination
delays or prevents spread to the cardiovascular system
in young mice, this strategy was not protective in aged
mice; spread to the cardiovascular system was observed
in 82% of aged, vaccinated mice by 28 days p.i.
These data suggest that, despite reports of intrinsic
and extrinsic age-associated defects in CTL [12,13] in-
cluding alterations in the diversity repertoire [reviewed
in [14]], CD8+ CTL precursor, vaccine epitope-specific,
cells must be induced in sufficient frequencies in aged
mice to mount a protective response in the lung that
closely parallels that seen in their young counterparts.
However, the CD8+ CTL response generated by the vac-
cine is not sufficient to provide long-term cardiovascular
protection, especially in aged animals. One possibility is
that extrinsic factors that could decrease the CTL re-
sponse generated to the vaccine in aged mice may vary by
site. Thus, the CTL response elicited by the vaccine, while
remaining effective in the lungs, may have been inhibitedin the cardiovascular system of aged mice via CD4+CD25
+FoxP3+ regulatory cells, which increase in number during
aging [15]. Another possible explanation of these findings
is that the immune mechanisms that control respiratory
C. pneumoniae burden differ from those that regulate
extra-respiratory spread or the establishment of systemic
infection. In this scenario, the CTL response generated by
the vaccine may not prevent or may even promote spread
to the cardiovascular system [11]. Finally, it is possible that
non-immune age-related processes, such as atheroscler-
osis, contribute to the higher burden of cardiovascular in-
fection and/or relative lack of vaccine efficacy in the aged.
Wild type C57BL/6 mice fed normal low-fat laboratory
chow, even at advanced age, do not show significant ath-
erosclerotic changes within the aorta [16]. Still, other age-
related changes inherent to or affecting the vascular endo-
thelium may promote infection of these cells and thus,
contribute to the burden of C. pneumoniae in the hearts/
ascending aortae of aged mice.Abbreviations
CTL: Cytotoxic T lymphocyte; IFU: Infection forming units; HBSS: Hanks
buffered salt solution; PBS: Phosphate buffered saline.
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